Drug Origin Transparency Act of 2026
- Bill Number
- H.R. 8339
- Origin Chamber
- House
- Congress
- 119th Congress, Session 2
- Status
- Introduced
- Latest Action
- 2026-04-16: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-04-23T09:38:26Z
AI-Generated Summary
Purpose
The Drug Origin Transparency Act of 2026 aims to increase transparency in the U.S. drug supply chain by requiring detailed reporting on manufacturing sources and enhanced labeling of drugs and active pharmaceutical ingredients (APIs, the key chemical components that make drugs effective).
Key Provisions
- Enhanced Reporting (Section 2):
- Amends existing annual reports on drug manufacturing volumes (under Section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act).
- Requires reports to include supply chain details, such as:
- Identities of suppliers for APIs, API intermediates (partly processed ingredients), and in-process materials.
- Amounts of the drug produced using materials from each supplier.
- Reports must be submitted more often than yearly (up to 4 times per year), as set by FDA regulations or guidance.
- New requirements start 6 months after FDA issues final rules.
- New Labeling Requirements (Section 3):
- Drugs and APIs must have labels showing the name, place of business, and unique facility identifier (a code identifying the manufacturing site) of the original manufacturer.
- Certificates of analysis for APIs (documents verifying quality) must include original manufacturer details.
- Labels must list:
- Original manufacturer(s) of each API.
- All manufacturers (if different from original).
- Packer or distributor, if applicable.
- FDA can allow flexibility, such as variations, alternative placements, or electronic labeling.
Significant Changes to Existing Law
- Reporting: Builds on current annual facility registration and drug volume reports by adding supply chain supplier identities and production amounts; shifts to more frequent submissions.
- Labeling: Expands misbranding rules (Section 502) to mandate origin and supply chain info on labels, which was not previously required. Existing labels already need name/place of packer/distributor, but this adds manufacturer and API specifics.
Potential Impacts
- Government Agencies: FDA gains detailed supply chain data for better oversight of drug safety, quality, and shortages; may need resources for new regulations and enforcement.
- Citizens: Improved traceability could enhance drug safety by helping identify risks like contaminated or counterfeit ingredients; consumers, doctors, and pharmacies get clearer origin info.
- International Relations: Affects global supply chains, as foreign suppliers (common for APIs) must provide data; could pressure countries with opaque manufacturing to improve standards.
Main Stakeholders Affected
- Drug Manufacturers and Suppliers: Must report detailed supply chain info and update labels/certificates (increased compliance costs).
- FDA: Oversees implementation via regulations; enforces via misbranding actions.
- Healthcare Providers and Consumers: Benefit from transparent labeling for informed choices.
- Importers/Distributors: Need to ensure compliance throughout the chain.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens FDA enforcement against misbranded drugs; provides regulatory flexibility to ease industry burden. No direct challenges to free speech or property rights noted.
- Constitutional: Aligns with Congress's commerce clause authority over interstate drug trade.
- Political: Bipartisan sponsors (Democrats and Republicans); addresses drug supply vulnerabilities exposed by shortages and quality issues, potentially reducing reliance on foreign APIs without trade restrictions.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Matsui, Doris O. [D-CA-7]
Cosponsors (3)
Rep. Crenshaw, Dan [R-TX-2], Rep. Schrier, Kim [D-WA-8], Rep. Hinson, Ashley [R-IA-2]
Recent Actions
- 2026-04-16: Referred to the House Committee on Energy and Commerce.
- 2026-04-16: Introduced in House
- 2026-04-16: Introduced in House
Bill Versions
- Drug Origin Transparency Act of 2026 — issued 2026-04-16 — PDF (5 pages)